3,061 Shares in LeMaitre Vascular, Inc. $LMAT Bought by Inceptionr LLC

Inceptionr LLC purchased a new stake in LeMaitre Vascular, Inc. (NASDAQ:LMAT) in the second quarter, Holdings Channel.com reports. The fund purchased 3,061 shares of the medical instruments supplier’s stock, valued at approximately $254,000.

A number of other hedge funds have also recently bought and sold shares of the company. Advisors Asset Management Inc. grew its stake in shares of LeMaitre Vascular by 3.0% in the 2nd quarter. Advisors Asset Management Inc. now owns 4,111 shares of the medical instruments supplier’s stock worth $341,000 after acquiring an additional 118 shares in the last quarter. Laurel Wealth Advisors LLC lifted its position in shares of LeMaitre Vascular by 8,205.6% during the second quarter. Laurel Wealth Advisors LLC now owns 1,495 shares of the medical instruments supplier’s stock valued at $124,000 after purchasing an additional 1,477 shares in the last quarter. XTX Topco Ltd purchased a new position in LeMaitre Vascular during the second quarter worth about $635,000. Prudential Financial Inc. grew its position in LeMaitre Vascular by 6.5% in the 2nd quarter. Prudential Financial Inc. now owns 21,390 shares of the medical instruments supplier’s stock worth $1,776,000 after purchasing an additional 1,300 shares in the last quarter. Finally, Cynosure Group LLC grew its position in LeMaitre Vascular by 32.8% in the 2nd quarter. Cynosure Group LLC now owns 4,926 shares of the medical instruments supplier’s stock worth $409,000 after purchasing an additional 1,217 shares in the last quarter. 84.64% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

LMAT has been the topic of several recent analyst reports. Roth Capital reissued a “buy” rating and set a $108.00 target price on shares of LeMaitre Vascular in a research report on Wednesday, November 5th. Barrington Research reissued an “outperform” rating and issued a $95.00 price objective on shares of LeMaitre Vascular in a research report on Wednesday, October 15th. Wells Fargo & Company reduced their price objective on LeMaitre Vascular from $97.00 to $93.00 and set an “equal weight” rating for the company in a research note on Friday, November 7th. Weiss Ratings reissued a “hold (c+)” rating on shares of LeMaitre Vascular in a report on Wednesday. Finally, Zacks Research upgraded shares of LeMaitre Vascular from a “hold” rating to a “strong-buy” rating in a report on Friday, November 7th. One equities research analyst has rated the stock with a Strong Buy rating, three have given a Buy rating and four have given a Hold rating to the stock. Based on data from MarketBeat, LeMaitre Vascular has a consensus rating of “Moderate Buy” and an average target price of $100.20.

LeMaitre Vascular Stock Down 0.5%

Shares of NASDAQ LMAT opened at $82.96 on Friday. The company has a debt-to-equity ratio of 0.46, a current ratio of 13.96 and a quick ratio of 11.74. The stock has a market capitalization of $1.88 billion, a PE ratio of 40.27, a P/E/G ratio of 2.29 and a beta of 0.77. LeMaitre Vascular, Inc. has a one year low of $71.42 and a one year high of $107.22. The business’s fifty day moving average price is $87.22 and its 200-day moving average price is $87.07.

LeMaitre Vascular (NASDAQ:LMAT) last announced its quarterly earnings data on Thursday, November 6th. The medical instruments supplier reported $0.62 earnings per share for the quarter, topping the consensus estimate of $0.57 by $0.05. The company had revenue of $61.05 million during the quarter, compared to analyst estimates of $62.18 million. LeMaitre Vascular had a return on equity of 13.67% and a net margin of 20.08%.The firm’s revenue for the quarter was up 11.4% on a year-over-year basis. During the same quarter last year, the firm posted $0.49 EPS. LeMaitre Vascular has set its FY 2025 guidance at 2.480-2.530 EPS. Q4 2025 guidance at 0.640-0.690 EPS. On average, equities research analysts anticipate that LeMaitre Vascular, Inc. will post 1.94 EPS for the current year.

LeMaitre Vascular Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Thursday, December 4th. Stockholders of record on Thursday, November 20th will be given a $0.20 dividend. The ex-dividend date of this dividend is Thursday, November 20th. This represents a $0.80 annualized dividend and a dividend yield of 1.0%. LeMaitre Vascular’s payout ratio is 34.48%.

About LeMaitre Vascular

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.